Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya27161Research ArticleClinical cases of the treatment of metastatic colorectal cancer in RussiaGoldbergV E-HasanovaA Ihaalfy@mail.ruShkuratovaV VShkuratovavv@mail.ruBelevichYu VBelevich-Julia@sibmail.comPopovaN O-SimolinaE I-VysockayaV V-DudnikovaE A-KravchukT L-MinnabetdinovaR Rrminnabetdinova@gmail.comNekrasovaO V-Research Institute of Oncology of the Tomsk National Research Medical Center of the Russian Academy of SciencesRepublican Clinical Oncologic DispensaryMultidisciplinary Clinical Medical Center “Medical city”15122017194394409042020Copyright © 2017, Consilium Medicum2017The article presents the clinical cases of the targeted therapy regorafenib in metastatic colorectal cancer (mCRC) in Russia. Russian oncologists’ experience has not only confirmed the results of international clinical trials, but also clearly demonstrated the possibility of regorafenib long-term administration on the back of high efficacy and manageable safety profile.colorectal cancer (CRC)targeted therapyregorafenibколоректальный рактаргетная терапиярегорафениб[Состояние онкологической помощи населению России в 2015 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. ФГБУ «МНИОИ им. П.А.Герцена» Минздрава России. М., 2016.][Shwartzberg L.S. et al. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovotin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 2014; 32: 2240-7.][Cremolini C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-15.][Переводчикова Н.И. Химиотерапия злокачественных опухолей. М.: Медицина, 1976.][Ahmann F.R, Garewal H, Greenberg B.R. Phase II Trial of High-Dose Continuous Infusion 5-FU with Allopurinol Modulation in Colon Cancer. Oncology 1986; 43 (2).][Abad A. et al. Sequential methotrexate, 5-FU and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial. Cancer 1995; 75 (6): 1238-44.][Peeters M. et el. Randomized Phase III Study of Panitumumab with Fluorourcil, Leucovorin and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone Second-Line Treatment in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2010; 28: 4706-13.][Douillard J.Y. et al. Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013; 369: 1023-43.][Van Cutsem E. et al. Fluorourcil, Leucovorin and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin Oncol 2015; 33: 692-700.][Bokemeyer C. et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015; 51: 1243-52.][Инструкция по применению лекарственного препарата для медицинского применения. Стиварга, № ЛП-003405 от 12.01.2016.][Инструкция по применению лекарственного препарата для медицинского применения. Стиварга, № ЛП-002534 от 15.07.2014.][Sastre J, Argile´s G. et al. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. Clin Transl Oncol 2014; 16: 942-53.][Kidd M.T, Wilcox R.E, Rogers J. et al. Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33 (Suppl. 3; abstr. 678).][Трякин А.А. Место регорафениба в лечении метастатического колоректального рака. Современная Онкология. 2016; 18 (2): 52-6.][Практические рекомендации по лекарственному лечению рака прямой кишки Российского общества клинической онкологии (RUSSCO). Версия 2017 г.][Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения Российского общества клинической онкологии (RUSSCO). Версия 2017 г.][Клинические рекомендации по лечению рака прямой кишки Ассоциации Онкологов России, версия 2017 г.][Клинические рекомендации по лечению рака ободочной кишки и ректосигмоидного отдела Ассоциации Онкологов России, версия 2017 г]